Although Diffuse Large B-Cell lymphoma (DLBCL) represents 30% of all non-Hodgkin lymphomas, there are many different subtypes of DLBCL with various prognostic implications. We are now recognizing that the molecular subtype of the DLBCL may be associated with specific clinical characteristics as well as outcome of the treatment. With this additional information, we may be able to better select a treatment for the patient which will improve the expected response. Only large scale clinical testing will help us with understanding these molecular subtypes and designing therapies for patients with DLBCL.
ASJC Scopus subject areas